In Case You Missed It
Before the Bell
Jim Cramer's Daily Booyah
Winners & Losers
Get the (PANC) Report Here
Trade with Jim Cramer 14 Days FREE
Myriad Genetics shares were soaring Tuesday after the firm announced a healthy second quarter that beat analyst expectations.
Panacos is worth more than 12 cents -- and is worth hanging on to.
Savient Pharmaceuticals on Monday released new safety data linking its gout drug Puricase to serious cardiovascular side effects.
Confessions of a former Panacostal; weighing Indevus' chances after its latest FDA blow; and more Elan.
Medarex refuses to face reality about the trial failure of its skin cancer drug.
Immucor slumps on an FTC investigation.
Microsoft led the after-hours charge, following an earnings beat.
This week: Biogen Idec and Neurocrine Biosciences.
Panacos falls on the departure of its CFO as well as a downgrade.
McCormick & Schmick's slides on lowered guidance.
Peyton Marshall leaves to 'pursue other opportunities.'
Abandoned by investors, Genelabs and Panacos Pharma are worth a second look.
Hoku Scientific climbs on news of a signed contracted.
Positive results from Australia could mean big things in the U.S.
Wireless Facilities falls after saying it needs to restate results.
FedEx's miss gets folks worried about 'non confirmation'. Plus, the M&A wave rolls on.
Panacos falls on disappointing study data for its HIV treatment.
Shares of Anadys Pharmaceuticals drop after the company announces the planned departure of its CEO.
Charles & Colvard issues a first-quarter sales warning, sending shares sliding.
If history is a guide, the stock could be gearing for another major rise. Plus the Nasdaq, NetEase and more.
Its chart indicates as much. Plus charts on the Nasdaq, Panacos, Charles Schwab, and more.
Wright Medical falls following the resignation of its CEO.
The stock is near the top of an uptrend channel. Plus the Nasdaq, Abgenix and more.
Big drugmakers are pursuing biotech outfits and making the small fry more willing to sell.
Also, Banco Bradesco is muy caliente.
The biotech's shares are underpriced, and its HIV drug holds great promise.
Cramer says it's worth waiting for this stock to drop down before buying.
There's little fallout Monday from a scandal that rocked the nation's financial markets Friday.
Biolase believes shareholders will be better served by eliminating its dividend.
©1996-2016 TheStreet, Inc. All rights reserved.
Action Alerts PLUS is a registered trademark of TheStreet, Inc.